Research programme: Alzheimer's disease vaccines - Merck
Latest Information Update: 31 Mar 2010
At a glance
- Originator Merck & Co
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Jan 2008 Coley Pharmaceutical Group has been acquired by Pfizer
- 16 Apr 2007 Preclinical trials in Alzheimer's disease in USA (Parenteral)